 Emmaus Life Sciences Inc OTCQX:EMMA has reported net revenue of 4.9 million for the third quarter of 2022, nearly 15 higher than the 4.3 million recorded in the second quarter, boosted primarily by its sickle cell oral therapy Endari in the United Arab Emirates after it was approved for sale in May this year. We enjoyed a third straight substantial increase in quarterly net revenue due to increased sales in the Middle East North Africa region. 